Arca BioPharma hopeful about personalized beta blocker

07/28/2008 | American City Business Journals

Arca BioPharma is inching closer to launching bucindolol, an experimental beta blocker that would be the first genetically targeted heart-failure drug. The biotech firm intends to file this week for FDA approval of the drug along with a genetic test being developed by partner Lab Corp.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA